For poultry fattening, the application of Sangrovit Extra at its maximum permitted level was not anticipated to raise significant consumer concerns. Despite its irritating effect on the eyes, the additive demonstrated no skin irritation or sensitization potential. The FEEDAP Panel was unable to rule out the possibility of the additive acting as a respiratory sensitizer. Exposure of unprotected individuals to sanguinarine and chelerythrine is a possible outcome of additive handling. Consequently, minimizing user exposure is crucial for mitigating risk. Considering the proposed conditions for use, Sangrovit Extra's application as a feed additive presented no environmental risk. Selleck SN-001 The addition of Sangrovit Extra to complete feed at 45mg/kg presented a potential for improved chicken fattening performance. This finding was generalized to include chickens raised for egg-laying or breeding purposes, and then applied to all poultry breeds used for meat production or reproduction.

The European Commission prompted EFSA to provide a new scientific opinion on the utilization of monensin sodium (Elancoban G200) as a feed additive for the fattening of both chickens and turkeys. The Panel, upon consideration of the new data, alters its prior conclusions. Monensin sodium results from fermentation by a non-genetically modified Streptomyces sp. strain. To properly document this particular organism, the reference NRRL B-67924 is crucial. A study of the genome structure suggests that the producing strain could potentially classify as a new species within the Streptomyces taxonomic group. The final additive was definitively ascertained to be free of the production strain and its DNA. Monensin is the only antimicrobial agent present in the product. Due to a dose-dependent reduction in final body weight of chickens for fattening and laying, the FEEDAP Panel is unable to determine the safety of monensin sodium (Elancoban G200) at the suggested maximum dose in feed. The product obtained from the ATCC 15413 parental strain was used in investigations of monensin sodium's toxicological profile. Following genomic analysis of the two strains, the FEEDAP Panel affirmed toxicological equivalence. This confirms the applicability of conclusions about Elancoban G200 to the product made with the new production strain, thereby proving its safety for the environment and consumers. The new strain introduces no additional risk in terms of consumer safety. Safe for turkeys up to sixteen weeks of age, Elancoban G200's monensin sodium, at 100 milligrams per kilogram of feed, shows potential for controlling coccidiosis at a minimum concentration of 60 milligrams per kilogram of complete feed.

Upon the European Commission's request, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was tasked with formulating a scientific assessment of the effectiveness of the additive containing Companilactobacillus farciminis (formerly Lactobacillus farciminis) CNCM I-3740 (trade name Biacton) for fattening chickens, fattening turkeys, and laying hens. The additive is characterized by the presence of viable C.farciminis CNCM I-3740 cells, with a minimum concentration of 1109 colony-forming units per gram. To enhance the fattening and productivity of chickens, turkeys, and laying hens, this zootechnical additive is incorporated in their complete feed at the recommended level of 5108 CFU per kilogram. Previous analyses and the presented data did not allow for the derivation of any conclusions about the additive's efficacy in any of the target species. Regarding the fattening of chickens, previous analyses revealed that supplementing with the additive at the prescribed level led to considerably greater weight or weight gains in the supplemented birds compared to the control group in only two instances. The efficacy trial's statistical analysis yielded new data, which were submitted. A significant enhancement in feed-to-gain ratios was observed in fattening chickens supplemented with Biacton at 85108 CFU/kg feed or more, in contrast to control birds and those receiving the recommended additive levels. The panel's report concluded that Biacton is likely to be effective in fattening chickens when administered at a concentration of 85108 CFU per kilogram of complete feed. Turkeys, specifically for fattening, were found to align with this conclusion's findings.

In response to a directive from the European Commission, EFSA was mandated to provide a scientific opinion on the safety and efficacy of potassium ferrocyanide as a functional anticaking agent in animal feed, suitable for all animal species. Potassium ferrocyanide, as an additive, is designed for use within potassium chloride, restricted to a maximum of 150 milligrams of ferrocyanide anion per kilogram of salt. Potassium ferrocyanide, at a maximum concentration of 150 mg of anhydrous ferrocyanide anions per kg of potassium chloride, is a safe addition for fattening and lactating pigs, sheep, goats, salmon, and dogs. The proposed conditions for potassium chloride use are deemed unsafe for fattening chickens, laying hens, turkeys, piglets, veal calves, cattle, dairy cows, horses, rabbits, and cats, lacking a safety margin. Owing to the paucity of information on potassium chloride usage in the diets of other animal species, a safe level of potassium chloride, supplemented with 150mg of ferrocyanide per kilogram, cannot be determined. From a consumer safety perspective, the application of potassium ferrocyanide in animal feed is not a matter of concern. Through in vivo studies, it was established that potassium ferrocyanide is not an irritant to the skin and eyes, and it does not cause skin sensitization. Nevertheless, the presence of nickel compels the categorization of the additive as a respiratory and dermal sensitizer. Concerning the additive's safety in soil and marine environments, the FEEDAP Panel's conclusions are hindered by the present data, yet its application in land-based aquaculture under the stipulated conditions is considered innocuous. Potassium ferrocyanide, at the suggested dosage in potassium chloride, is recognised as a powerful anticaking agent.

The European Commission solicited a scientific opinion from EFSA regarding the renewal application of Pediococcus pentosaceus NCIMB 30168 as a technological feed additive for all kinds of animals. The applicant's submitted proof validates the currently marketed additive's adherence to the existing authorization conditions. No novel evidence compels the FEEDAP Panel to revisit its previous determinations. Consequently, the Panel maintains that the additive, under its stipulated conditions, remains safe for all animal species, consumers, and the environment. Concerning user safety, the additive warrants consideration as a respiratory sensitizer. No inferences can be made about the additive's ability to cause skin sensitization or irritation to the skin or eyes. Assessing the additive's efficacy isn't necessary during the authorization renewal process.

The feed additive under review, Ronozyme Multigrain G/L, comprises endo-14-beta-xylanase, endo-14-beta-glucanase, and endo-13(4)-beta-glucanase, all derived from a non-genetically modified Trichoderma reesei (ATCC 74444) strain. This product, classified as a digestibility enhancer, is approved for use in poultry for fattening, poultry for laying, and weaned piglets as a zootechnical additive. The renewed authorization of the additive is the subject of this scientific opinion, considering the species and categories which currently have an existing authorization. The applicant's evidence indicated the current market additive is in accordance with the authorization's specifications. The EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) has, based on a comprehensive analysis of recent data, reached the conclusion that there is no fresh evidence compelling a modification of the previously established safety assessments of the additive for animal species/categories, consumers, and the environment under the currently authorized conditions of use. The additive's potential to act as a respiratory sensitizer should be a primary concern for user safety. Due to a lack of data, the Panel was unable to determine if the additive could cause skin or eye irritation, or skin sensitization. In the context of poultry fattening, laying hens, and weaned piglets' authorization renewal, the efficacy of the additive did not need to be evaluated.

Acting on the European Commission's request, the EFSA Panel on Nutrition, Novel Foods, and Food Allergens (NDA) presented an opinion on the classification of 3-fucosyllactose (3-FL) as a novel food (NF) in accordance with Regulation (EU) 2015/2283. vaccines and immunization The NF is principally made up of the human-identical milk oligosaccharide (HiMO) 3-FL, but it is also comprised of d-lactose, l-fucose, 3-fucosyllactulose, and a small amount of other related saccharides. Through fermentation, the genetically modified strain of E. coli K-12 DH1 (MDO MAP1834, DSM 4235) creates the NF. No safety issues arise from the information detailing the NF's production methods, ingredient makeup, and technical specifications. The applicant intends to incorporate NF into a comprehensive list of foods, such as infant formula and follow-on formula, medical foods, and nutritional supplements (FS). The focus of this research is on the broader general population. The maximum daily intake of 3-FL, considering both proposed and combined (authorized and proposed) applications at their highest usage levels across all demographic groups, remains below the highest 3-FL intake observed in human milk-fed infants, when calculated per unit of body weight. Breastfed infants' intake of 3-FL, normalized by body weight, is predicted to be a safe level for application to other population categories as well. There is no safety concern associated with the ingestion of other carbohydrate compounds that share a similar structure to 3-FL. Drug response biomarker The simultaneous ingestion of foods with added 3-FL or human milk and FS is not recommended.